DLBCL is the most common type of aggressive lymphoma NHL. DLBCL is a heterogeneous disease that can arise from de novo or malignant transformation of more indolent lymphomas. The cells in DLBCL are derived from mature naïve B-cells in the germinal center or post germinal center of lymph nodes which are organized in a diffuse pattern and efface the normal nodal architecture. DLBCL can be classified into different entities based on molecular features which have an impact on the prognosis. Gene expression profiling (GEP) categorized DLBCL based on the cell of origin into germinal B-cell like (GBC), activated B-cell like (ABC), or unclassified. The current standard of care for first line treatment of DLBCL is R‐CHOP, can cure approximately 60% to 70% of patients with DLBCL . Despite progress in the upfront treatment relapse rate is reported to be between 30% and 40%. At disease progression or relapse, standard treatment for transplant eligible patients is salvage chemotherapy followed by ASCT. Patients with R/R DLBCL that are transplant ineligible or who have failed SCT have limited therapeutic options and poor prognosis